Acrivon Therapeutics
Watertown, Massachusetts, United States · Biopharma, Biotechnology, Health Care
Acrivon Therapeutics is a precision oncology therapeutics company uniquely enabled by a differentiated proteomics-based patient selection platform. Our method is widely applicable across drug classes and modalities. We specifically apply our approach to challenging oncology drug targets causally implicated in the vast majority of cancers, particularly those without simple single gene driver mutati
You have opened 5 full company profiles today. Create an account to keep reading them. Create an account
Key facts
- Headquarters
- Watertown, Massachusetts, United States
- Employees
- Unknown
- Industries
- Biopharma, Biotechnology, Health Care
- Status
- Public (ACRV)
- Website
- acrivon.com
- Company page
Recent activity at Acrivon Therapeutics
- : Acrivon Appoints Michaela Levin as Chief Business Officer
- : SEC 8-K (5.02): On June 17, 2026, Acrivon Therapeutics, Inc. held its 2026 annual meeting of stockholders where stockholders approved the Amended and Restated 2022 Equity Incentive Plan, enhancing the company's ability to provide equity-based awards to employees and directors. The plan includes an increase of 3,000,000 shares, raising the total to 8,606,723 shares available for issuance. Additionally, the annual meeting resulted in the election of Michael Tomsicek, M.B.A. and Charles Baum, M.D., Ph.D. as Class I Directors, reinforcing new leadership within the company. This strategic decision aims to secure key talent and incentivize performance aligned with stockholder interests.
- : SEC 8-K (7.01): The Company, Acrivon Therapeutics, Inc., disclosed a recent corporate presentation posted on its website that provides an update on its business activities, particularly related to its ACR-368 phase 2b study targeting serous type endometrial cancer patients. The presentation details the initiation of arm 4 of the study based on encouraging clinical data, specifically aimed at studying ACR-368 monotherapy in subjects with up to two prior lines of therapy. Additionally, it notes the completion of exploratory arm 2 that tested ACR-368 supported by ultra low dose gemcitabine in BM- subjects. This event, critical for the Company's clinical outcomes, reflects ongoing commitment to advancing its pipeline. The disclosed information was made public on March 19, 2026.
Employee benefit plans
Acrivon Therapeutics files 1 employee benefit plan with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.
About Acrivon Therapeutics: questions and answers
What does Acrivon Therapeutics do?
Acrivon Therapeutics is a precision oncology therapeutics company uniquely enabled by a differentiated proteomics-based patient selection platform. Our method is widely applicable across drug classes and modalities. We specifically apply our approach to challenging oncology drug targets causally implicated in the vast majority of cancers, particularly those without simple single gene driver mutati
Where is Acrivon Therapeutics headquartered?
Acrivon Therapeutics is headquartered in Watertown, Massachusetts, United States.
What is the latest news on Acrivon Therapeutics?
On Aug 31, 2026, Acrivon Appoints Michaela Levin as Chief Business Officer
Is Acrivon Therapeutics a public company?
Yes. Acrivon Therapeutics is publicly traded under the ticker ACRV.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy